Pathology Oncology Research

, Volume 6, Issue 1, pp 65–70 | Cite as

Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: Anin situ hybridization analysis

  • Don Kristt
  • Isaac Turner
  • Rumelia Koren
  • Edward Ramadan
  • Rivka Gal


Increased expression of a key cell cycle regulator, cyclin Dl, may have relevance to carcinogenesis and clinicopathological characteristics of some cancers. This study represents the first application ofin situ hybridization, ISH, to detect cyclin Dl mRNA in tissue sections from colorectal carcinomas. This approach was selected because of its unique potential to clarify whether increased expression of cyclin Dl mRNA correlates with clinical and pathological parameters. The ISH of a non-radioactive oligonucleotide probe (Biogenex) was immunocytochemically detected in paraffin embedded sections from biopsy or resection specimens. Tumors ranged from well to poorly differentiated, and from stages A, B, C, and D. Ten year survival data were available on the majority of patients. Intensity of tumor and background (smooth muscle) signals were independently scored from 0 to 3. Overexpressed cyclin Dl mRNA was seen in 86% of cases compared to back-ground. This frequency is similar to that reported for pancreatic carcinoma. The average signal intensity score in tumor foci was 1.9 with a background score of 0.05 (p < 001). All cases showed specific staining judged by the cytoplasmic localization and a tumor signal:background ratio > 1. Expression did not differentiate cancers based on grade, stage or survival (p>l), but did differentiate carcinoma and severe dysplasia from mild dysplasia. We conclude that ISH of cyclin Dl mRNA is an effective and relatively specific means of detecting activity of this gene in colonic neoplasms. The high frequency of overexpression implies that gene activity by itself is not likely to predict a tumor’s biological or clinical behavior. On the other hand, these data suggest that increased cyclin Dl gene activity may be an early event in colorectal carcinogenesis. They also are consistent with findings showing cyclin Dl is inducible by a variety of oncogene products.


cyclin Dl in situ hybridization mRNA colon cancer colorectal carcinoma survival grade stage 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.2
    Alperts B, Bray D, Lewis J, et al. Molecular biology of the cell. 2nd ed. Garland Publ, New York-London, 481–549, 1989.Google Scholar
  2. 2.2
    Arber N, Hibshoosh H, Moss SF, et al: Increased expression of cyclin Dl is an early event in multistage colorectal carcinogenesis. Gastroenterology 110:669–674, 1996.PubMedCrossRefGoogle Scholar
  3. 3.2
    Bartkova J, Lukas J, Strauss M, et al:The PRAD-1/cyclin Dl oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 58:568–573, 1994.PubMedCrossRefGoogle Scholar
  4. 4.2
    Bartkova J, Lukas J, Strauss M, et al: Cell cycle-related variation and tissue restricted expression of human cyclin Dl protein. J Pathol 172:237–245, 1994.PubMedCrossRefGoogle Scholar
  5. 5.2
    Bates S, Bonetta L, MacAllan D, et al: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin Dl. Oncogene 9:71–79, 1994.PubMedGoogle Scholar
  6. 6.2
    Betticher D, Heighway J, Hasleton PS, et al: Prognostic significance of CCND1 (cyclin Dl) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73:294–300, 1996.PubMedGoogle Scholar
  7. 7.2
    Bodrug S, Warner B, Bath M, et al Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13:2124–2130, 1994.PubMedGoogle Scholar
  8. 8.2
    Chen X, Bargonetti J, Prives C: p53, through p21 (WAF1/CIP1), induces cyclin Dl synthesis. Cancer Res. 55:4257–4263, 1995.PubMedGoogle Scholar
  9. 9.2
    Dowdy SF, Hinds PW, Louie K, et al: Physical interaction of the retinoblastoma proteins with human D cyclins. Cell 73:499–511, 1993.PubMedCrossRefGoogle Scholar
  10. 10.2
    Filmus J, Robles AL, Shi W, et al: Induction of cyclin Dl overexpression by activated ras. Oncogene 9:3627–3633, 1994.PubMedGoogle Scholar
  11. 11.2
    Gansauge S, Gansauge F, Ramadani M, et al: Overexpression of cyclin Dl in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57:1634–1637, 1997.PubMedGoogle Scholar
  12. 12.2
    Gillett C, Fantl Y, Smith R, et al: Amplification and overexpression of cyclin D1 in breast cancer detect by immunohistochemical staining. Cancer Res54:1812–1817, 1994.PubMedGoogle Scholar
  13. 13.2
    Hosokawa Y, Arnold A: Mechanism of cyclin Dl (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele -specific expression. Genes Chromosomes Cancer 22:66–71, 1998.PubMedCrossRefGoogle Scholar
  14. 14.2
    Hunter T, Pines J: Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell 79:573–582, 1994.PubMedCrossRefGoogle Scholar
  15. 15.2
    Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980–2983, 1992.PubMedGoogle Scholar
  16. 16.2
    Kallakury BV, Sheehan CE, Ambros RA, et al: The prognostic significance of p34cdc2 and cyclin Dl protein expression in prostate adenocarcinoma. Cancer 80:753–763, 1997.PubMedCrossRefGoogle Scholar
  17. 17.2
    Kristt DA, Winston GJ, Melloul, et al: Patterns of proliferative changes in crypts bordering colonic tumors: zonal histology and cell cycle marker expression. Pathol Oncol Res 5:297–303, 1999.PubMedCrossRefGoogle Scholar
  18. 18.2
    Kuroda H, Komatsu H, Nakamura S, et al: The positive nuclear staining observed with monoclonal antibody against PRADl/cyclin Dl correlates with mRNA expression in mantle cell lymphoma. Jpn J Cancer Res. 86:890–898, 1995.PubMedGoogle Scholar
  19. 19.2
    Lovec H, Sewing A, Lucibello FC, et al: Oncogenic activity of cyclin Dl revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene 9:323–326, 1994.PubMedGoogle Scholar
  20. 20.2
    Margiotta M, Forde A, Gallery F, et al: Comparison of three commercial kits for in situ detection of viral DNA. J Histochem 19:139–142, 1996.Google Scholar
  21. 21.2
    Matsushime H, Roussel MF, Ashmun RA, et al: Colony-stimulating factor 1 regulates novel cyclins during the Gl phase of the cell cycle. Cell 65:701–715, 1991.PubMedCrossRefGoogle Scholar
  22. 22.2
    Naitoh H, Shibata J, Kawaguchi A, et al: Overexpression and localization of cyclin Dl mRNA and antigen in esophageal cancer. Am J Pathol 146:1161–1169, 1995.PubMedGoogle Scholar
  23. 23.2
    Pagano M, Theodoras AM, Tam SW, et al: Cyclin Dl -mediated inhibition of repair and replication DNA-synthesis in human fibroblasts. Genes Dev 8:1627–1639, 1994.PubMedCrossRefGoogle Scholar
  24. 24.2
    Sutter T, Doi S, Carnevale KA, et al: Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 28:285–309, 1997.PubMedGoogle Scholar
  25. 25.2
    Zhang Y-J, Jiang W, Chen CJ, et al: Amplification and overexpression of cyclin Dl in human hepatocellular carcinoma. Biochem Biophys Res Comm 196:1010–1016, 1993.PubMedCrossRefGoogle Scholar
  26. 26.2
    Zhou P, Jiang W, Zhang Y-J, et al: Antisense to cyclin Dl inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11:571–580, 1995.PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2000

Authors and Affiliations

  • Don Kristt
    • 1
  • Isaac Turner
    • 1
  • Rumelia Koren
    • 1
  • Edward Ramadan
    • 2
  • Rivka Gal
    • 1
  1. 1.Department of PathologyRabin Medical Center (Golda Campus)Petach TikvahIsrael
  2. 2.Department of Surgery ARabin Medical Center (Golda Campus)Petach TikvahIsrael

Personalised recommendations